Announcements
- Cytek® Biosciences Names William McCombe Chief Financial Officer
- Cytek® Biosciences Opens New Facility to Address Increasing Global Demand for Cutting-Edge Cell Analysis Solutions
- Cytek Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
- Cytek Biosciences to Participate in Upcoming Investor Conferences
- Cytek Biosciences to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
- Cytek® Biosciences Signs Agreement with CRG and UPF to Accelerate Scientific Discoveries
- Cytek Biosciences Announces Preliminary Full Year 2023 Revenue Results
- Cytek Biosciences to present at the 42nd Annual J.P. Morgan Healthcare Conference
- Cytek® Biosciences Introduces the Cytek Orion™ Reagent Cocktail Preparation System, the First-of-its-Kind Automated Cocktail Preparation Instrument for Flow Cytometry
- Cytek Biosciences to participate in the Piper Sandler 35th Annual Healthcare Conference
More ▼
Key statistics
On Wednesday, Cytek Biosciences Inc (8EQ:FRA) closed at 3.40, 0.00% above its 52-week low of 3.40, set on Nov 08, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 3.40 |
Average volume | -- |
---|---|
Shares outstanding | 130.82m |
Free float | 119.43m |
P/E (TTM) | -- |
Market cap | 781.02m USD |
EPS (TTM) | -0.0887 USD |
Data delayed at least 15 minutes, as of Nov 08 2023 08:15 GMT.
More ▼